Novo’s Blockbuster Obesity Drug Wegovy Under Fire in Denmark
- Authority cites cost of $870,000 to prevent one cardiac event
- Denmark is pushing back as more experts question drug’s cost
This article is for subscribers only.
A Danish drug oversight panel advised doctors to restrict prescriptions of Novo Nordisk A/S’s blockbuster obesity drug Wegovy, saying the medicine is so expensive that it would cost about $870,000 to prevent a single heart attack, stroke or other severe cardiac problem.
Wegovy shouldn’t be a doctor’s first choice, and they should only start a “few” patients on the treatment, the Danish Health Authority’s Institute for Rational Pharmacotherapy said in a report released on June 6. Though the institute is influential, doctors have wide leeway to disregard its advice.